PRESS RELEASE. Capitainer, a Swedish MedTech company supplying reliable solutions for self-sampling of blood and plasma, has raised a further SEK 34 million with Sciety and its investment syndicate in a new share issue. The company will use the proceeds to fund additional product validations, sales, and marketing to meet the increased demand for Capitainer’s home-sampling products.

“We are delighted and appreciate the continued trust and interest from experienced life science investors. With Sciety and its investor syndicate, we have secured funding that makes it possible to meet the increased demand for our qDBS card for blood sampling at home. We will also use the new capital to increase our product development and grow our product platform, including collecting plasma and urine samples,” says Christopher Aulin, CEO of Capitainer.

Capitainer’s home sampling method is based on patented microfluidic technology. It results in an exact volume of blood that can be used to accurately quantify various analytes, circumventing the limitations of conventional DBS. For the patient, it is easy to use the qDBS card and then send it by regular mail to the laboratory. There is no need for refrigerated transport or special packaging.

The majority of all medical decisions are based on laboratory results, and every year billions of blood samples are collected, but the procedure is expensive and time-consuming. Remote self-sampling enables the patient to save both time and money.

During the covid-19 pandemic, the demand for self-sampling with Capitainer qDBS for antibody testing increased. A scientific study could also show that the method provided results with excellent accuracy. Both the public and experts experienced how convenient and essential it is to perform correct self-sampling both at home and work.

“We are pleased to invest an additional SEK 34 million in Capitainer, a company leading the way in its field. There is a great need for new and innovative solutions to streamline and facilitate sampling, even in the absence of a pandemic. Capitainer is at the forefront of a technology shift that creates new remote-care opportunities,” says Andreas Lindblom, CEO of Sciety.

Capitainer AB was founded in 2016 and is a supplier of intelligent solutions for collecting an exact amount of blood, plasma, or urine using capillary sampling and then saving the samples in dried form. The application is available in many market segments, including but not limited to therapeutic drug monitoring, biomarkers, genomics, drug development, and testing for drug abuse and doping. The company has a well-defined go-to-market strategy for new regions and a team with solid experience in sales and business development in life science.

Don’t miss out on important news and upcoming events

Do you want to know more about our selected companies and also get invitations to company presentation events where you will have the chance to meet the management?

Subscribe to our newsletter here.

About Sciety

Sciety is the leading Nordic life science and health tech investment syndicate. By combining experience in life science and finance, we select promising companies in the industry. We invest our funds in all companies that pass our selection process and offer the investment syndicate to co-invest on the same terms. The syndicate comprises venture capital firms, family offices, and business angels.

Our mission is to help life science innovations to reach their full potential.